Objective To estimate the prevalence of drug-resistant tuberculosis (TB) and describe the resistance patterns in patients commencing antiretroviral therapy (ART) in an HIV clinic in Durban, South Africa. Design Cross-sectional cohort study. Methods Consecutive HIV-infected adults (≥18y/o) initiating HIV care were enrolled from May 2007–May 2008, regardless of signs or symptoms of active TB. Prior TB history and current TB treatment status were self-reported. Subjects expectorated sputum for culture (MGIT liquid and 7H11 solid medium). Positive cultures were tested for susceptibility to first- and second-line anti-tuberculous drugs. The prevalence of drug-resistant TB, stratified by prior TB history and current TB treatment status, was assessed. Results 1,035 subjects had complete culture results. Median CD4 count was 92/μl (IQR 42–150/μl). 267 subjects (26%) reported a prior history of TB and 210 (20%) were receiving TB treatment at enrollment; 191 (18%) subjects had positive sputum cultures, among whom the estimated prevalence of resistance to any antituberculous drug was 7.4% (95% CI 4.0–12.4). Among those with prior TB, the prevalence of resistance was 15.4% (95% CI 5.9–30.5) compared to 5.2% (95% CI 2.1–8.9) among those with no prior TB. 5.1% (95% CI 2.4–9.5) had rifampin or rifampin plus INH resistance. Conclusions The prevalence of TB resistance to at least one drug was 7.4% among adults with positive TB cultures initiating ART in Durban, South Africa, with 5.1% having rifampin or rifampin plus INH resistance. Improved tools for diagnosing TB and drug resistance are urgently needed in areas of high HIV/TB prevalence.
References
[1]
World Health Organization. Tuberculosis Fact Sheet, Nov 2010. Available at: http://www.who.int/mediacentre/factsheet？s/fs104/en/. Accessed 25 April 2012.
[2]
World Health Organization. Global tuberculosis control2011. Available at http://www.who.int/tb/publications/globa？l_report/en/index.html. Accessed 25 April 2012.
[3]
Epidemiological Country Profile on HIV and AIDS: South Africa 2010. Available at: http://www.unaids.org/en/regionscountrie？s/countries/southafrica/. Accessed 25 April 2012.
[4]
Republic of South Africa Department of Health. Tuberculosis strategic plan for South Africa: 2007–2011. Available at: http://www.doh.gov.za/docs/index.html. Accessed 25 April 2012.
[5]
Andrews JR, Shah NS, Gandhi N, Moll T, Friedland G (2007) Multidrug-resistant and extensively drug-resistant tuberculosis: implications for the HIV epidemic and antiretroviral therapy rollout in South Africa. J Infect Dis 196 Suppl 3S482–490.
[6]
Harries AD, Zachariah R, Corbett EL, Lawn SD, Santos-Filho ET, et al. (2010) The HIV-associated tuberculosis epidemic–when will we act? Lancet 375: 1906–1919.
[7]
Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, et al. (2006) Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368: 1575–1580.
Moodley P, Shah NS, Tayob N, Connolly C, Zetola N, et al. (2011) Spread of extensively drug-resistant tuberculosis in KwaZulu-Natal province, South Africa. PLoS One 6: e17513.
[10]
Republic of South Africa. HIV and AIDS and STI strategic plan for South Africa, 2007–2011. Department of Health: 2007.
[11]
Republic of South Africa Department of Health. Tuberculosis control programme practical guidelines, 2004. Available at: http://www.kznhealth.gov.za/chrp/documen？ts/Guidelines/Guidelines%20National/Tube？rculosis/SA%20TB%20Guidelines%202004.pdf. Accessed 25 April 2012.
[12]
Bassett IV, Wang B, Chetty S, Giddy J, Losina E, et al. (2010) Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis 51: 823–829.
[13]
World Health Organization. Anti-tuberculosis drug resistance in the world. Available at http://whqlibdoc.who.int/hq/2008/WHO_HTM？_TB_2008.394_eng.pdf. Accessed 25 April 2012.
[14]
Gandhi NR, Shah NS, Andrews JR, Vella V, Moll AP, et al. (2010) HIV coinfection in multidrug- and extensively drug-resistant tuberculosis results in high early mortality. Am J Respir Crit Care Med 181: 80–86.
[15]
Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, et al. (2011) Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 377: 1495–1505.
[16]
Andrews JR, Gandhi NR, Moodley P, Shah NS, Bohlken L, et al. (2008) Exogenous reinfection as a cause of multidrug-resistant and extensively drug-resistant tuberculosis in rural South Africa. J Infect Dis 198: 1582–1589.
[17]
Republic of South Africa Department of Health. National tuberculosis management guidelines, 2008. Available at: http://www.hivfshealth.org/sites/default？/files/Draft%20National%20TB%20Guideline？%202008_2009.pdf. Accessed 25 April 2012.
[18]
Espinal MA (2003) Time to abandon the standard retreatment regimen with first-line drugs for failures of standard treatment. Int J Tuberc Lung Dis 7: 607–608.
